Methods of treating pulmonary disorders with liposomal amikacin formulations
AssigneeInsmed Incorporated
InventorRenu GUPTA
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period.
Claims21
1-50. (canceled)
A method of treating a pulmonary infection associated with bronchiectasis in a patient in need thereof, comprising administering to the lungs of the patient for at least one treatment cycle, an effective dose of a nebulized liposomal amikacin formulation comprising amikacin encapsulated in a liposome wherein the lipid component of the liposome comprises a phospholipid and a sterol, wherein:
- the treatment cycle comprises an administration period of 15 to 75 days followed by an off period of 15 to 75 days;
- during which an improvement in lung function is maintained for the patient, for at least 15 days after the administration period ends,
- and the effective dose comprises 100 mg to 1000 mg of amikacin daily during the administration period.
The method of claim 67, wherein the weight ratio of DPPC to cholesterol is 2:1.
The method of 51, wherein the pulmonary infection is a mycobacterial infection.
Dependencies are inferred from the claim text.